Bioventus (NASDAQ:BVS) Shares Down 8.2% – Here’s Why

Bioventus Inc. (NASDAQ:BVS) fell 8.2% on Friday . The stock traded as low as $8.32 and last traded at $8.35. 154,082 shares traded hands during mid-day trading, a decline of 43% from the average session volume of 272,240 shares. The stock had previously closed at $9.10.

Analysts Set New Price Targets

Several analysts recently commented on the company. Weiss Ratings reiterated a “hold (c-)” rating on shares of Bioventus in a research report on Monday, December 29th. Cantor Fitzgerald upgraded Bioventus to a “strong-buy” rating in a report on Wednesday. Finally, Barrington Research raised shares of Bioventus to a “strong-buy” rating in a research note on Monday, February 9th. Two analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Bioventus has an average rating of “Buy”.

Bioventus Stock Down 7.6%

The firm has a 50-day moving average of $8.12 and a two-hundred day moving average of $7.50. The company has a quick ratio of 1.14, a current ratio of 1.74 and a debt-to-equity ratio of 1.50. The company has a market capitalization of $696.01 million, a PE ratio of 25.48 and a beta of 0.78.

Bioventus (NASDAQ:BVS) last posted its earnings results on Thursday, March 5th. The company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.02. Bioventus had a return on equity of 29.99% and a net margin of 4.00%.The company had revenue of $157.90 million for the quarter.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.